Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Jul 21, 2026, 5:32 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Skin/Soft Tissue Infections Clear all
Not listed No phase listed Observational

Surveillance of Community-Associated MRSA

NCT04083092
View directory record Official record
Conditions
MRSA
Interventions
Not listed
Lead sponsor
Children's Healthcare of Atlanta
Other
Eligibility
6 Months to 21 Years
Enrollment
50 participants
Timeline
2019 – 2020
U.S. locations
1
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Sep 9, 2019 · Synced Jul 21, 2026, 5:32 PM EDT
Completed Phase 2 Interventional

Nicotine Skin Patch in Treating Patients With Kaposi's Sarcoma

NCT00295984
View directory record Official record
Conditions
Sarcoma
Interventions
nicotine
Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years to 78 Years
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Jun 19, 2013 · Synced Jul 21, 2026, 5:32 PM EDT
Completed Phase 1Phase 2 Interventional

Phase I/II Study of Escalating-Dose Melphalan w/Autologous SCS & Amifostine Cytoprotect

NCT00003425
View directory record Official record
Conditions
Breast Cancer, Leukemia, Lymphoma, Neuroblastoma, Ovarian Cancer, Sarcoma, Unspecified Adult Solid Tumor, Protocol Specific
Interventions
filgrastim, amifostine trihydrate, cyclophosphamide, melphalan, peripheral blood stem cell transplantation
Biological · Drug · Procedure
Lead sponsor
University of Kentucky
Other
Eligibility
14 Years to 70 Years
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 1997
U.S. locations
4
States / cities
Lexington, Kentucky • Baltimore, Maryland • Philadelphia, Pennsylvania + 1 more
Source: ClinicalTrials.gov public record
Updated Apr 25, 2013 · Synced Jul 21, 2026, 5:32 PM EDT
Completed Phase 1 Interventional

Combination Chemotherapy Plus Filgrastim in Treating Patients With Advanced Solid Tumors

NCT00014456
View directory record Official record
Conditions
Bladder Cancer, Breast Cancer, Carcinoma of Unknown Primary, Esophageal Cancer, Gastric Cancer, Head and Neck Cancer, Lung Cancer, Melanoma (Skin), Ovarian Cancer, Pancreatic Cancer, Prostate Cancer, Sarcoma
Interventions
filgrastim, docetaxel, gemcitabine hydrochloride
Biological · Drug
Lead sponsor
Dartmouth-Hitchcock Medical Center
Other
Eligibility
18 Years and older
Enrollment
35 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2000 – 2005
U.S. locations
1
States / cities
Lebanon, New Hampshire
Source: ClinicalTrials.gov public record
Updated Aug 27, 2013 · Synced Jul 21, 2026, 5:32 PM EDT
Completed Phase 2 Interventional Results available

Nelfinavir Mesylate in Treating Patients With Kaposi Sarcoma

NCT03077451
View directory record Official record
Conditions
Recurrent Kaposi Sarcoma, Skin Kaposi Sarcoma
Interventions
Laboratory Biomarker Analysis, Nelfinavir Mesylate
Other · Drug
Lead sponsor
AIDS Malignancy Consortium
Network
Eligibility
18 Years and older
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2023
U.S. locations
10
States / cities
Miami, Florida • Atlanta, Georgia • Baltimore, Maryland + 7 more
Source: ClinicalTrials.gov public record
Updated Dec 16, 2025 · Synced Jul 21, 2026, 5:32 PM EDT
Completed Not applicable Interventional

MicroMatrix® Flex in Tunneling Wounds

NCT06629506
View directory record Official record
Conditions
Pressure Injury, Venous Ulcer, Necrotizing Soft Tissue Infection, Diabetic Ulcers, Draining Wound
Interventions
MicroMatrix® Flex, MicroMatrix® UBM Particulate, Cytal® Wound Matrix 2-Layer
Device
Lead sponsor
Integra LifeSciences Corporation
Industry
Eligibility
22 Years and older
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2025
U.S. locations
3
States / cities
Aurora, Colorado • Washington D.C., District of Columbia • Lake Success, New York
Source: ClinicalTrials.gov public record
Updated Mar 4, 2026 · Synced Jul 21, 2026, 5:32 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Decreasing Antibiotic Duration for Skin and Soft Tissue Infection Using Behavioral Economics in Primary Care

NCT05226260
View directory record Official record
Conditions
Cellulitis, Abscess, Drain Abscess, Impetigo, Skin Infection, Antibiotic Duration, Behavioral Economics
Interventions
Default Duration order Panel
Behavioral
Lead sponsor
Nationwide Children's Hospital
Other
Eligibility
3 Months to 99 Years
Enrollment
1,634 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2025
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Apr 7, 2025 · Synced Jul 21, 2026, 5:32 PM EDT
Terminated Phase 1Phase 2 Interventional Results available

REVEAL Study of NKTR-262 in Combination With NKTR-214 and Nivolumab in Patients With Locally Advanced / Metastatic Solid Tumor Malignancies

NCT03435640
View directory record Official record
Conditions
Melanoma, Merkel Cell Carcinoma, Triple Negative Breast Cancer, Head and Neck Squamous Cell Carcinoma, Renal Cell Carcinoma, Colorectal Cancer, Sarcoma
Interventions
NKTR-262, bempegaldesleukin, nivolumab
Drug
Lead sponsor
Nektar Therapeutics
Industry
Eligibility
18 Years and older
Enrollment
64 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2022
U.S. locations
14
States / cities
Scottsdale, Arizona • La Jolla, California • Tampa, Florida + 11 more
Source: ClinicalTrials.gov public record
Updated Mar 7, 2023 · Synced Jul 21, 2026, 5:32 PM EDT
Completed Phase 4 Interventional Results available

Skin Structure Infections With Suspected or Proven Methicillin-Resistant Staphylococcus Aureus (MRSA)

NCT00087490
View directory record Official record
Conditions
Skin/Soft Tissue Infections, Methicillin Resistant Staphylococcus Aureus (MRSA)
Interventions
linezolid, vancomycin
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
1,077 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2007
U.S. locations
76
States / cities
Montgomery, Alabama • Tucson, Arizona • Los Angeles, California + 53 more
Source: ClinicalTrials.gov public record
Updated Aug 7, 2012 · Synced Jul 21, 2026, 5:32 PM EDT
Completed Phase 3 Interventional

Incision and Drainage Versus Needle Aspiration in Soft Tissue Abscesses

NCT01085929
View directory record Official record
Conditions
Abscess, Cellulitis
Interventions
Incision and Drainage, Ultrasound Guided Aspiration
Procedure
Lead sponsor
University of Massachusetts, Worcester
Other
Eligibility
18 Years and older
Enrollment
101 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
2
States / cities
Boston, Massachusetts • Worcester, Massachusetts
Source: ClinicalTrials.gov public record
Updated Mar 11, 2010 · Synced Jul 21, 2026, 5:32 PM EDT
Completed Phase 3 Interventional Results available

Phase 3 Study to Evaluate Safety and Efficacy of Iclaprim Versus Vancomycin for ABSSSI: REVIVE-1

NCT02600611
View directory record Official record
Conditions
Skin Structures and Soft Tissue Infections
Interventions
iclaprim, vancomycin
Drug
Lead sponsor
Motif Bio
Industry
Eligibility
18 Years and older
Enrollment
600 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
16
States / cities
Buena Park, California • La Mesa, California • Long Beach, California + 12 more
Source: ClinicalTrials.gov public record
Updated Jun 18, 2018 · Synced Jul 21, 2026, 5:32 PM EDT
Completed Phase 4 Interventional Results available

Skin and Soft Tissue Infection (SSTI) Study

NCT02600871
View directory record Official record
Conditions
Skin Diseases, Infectious, Soft Tissue Infections
Interventions
Provodine, Incision and Drainage
Drug · Procedure
Lead sponsor
The University of Texas Health Science Center at San Antonio
Other
Eligibility
18 Years and older
Enrollment
101 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
1
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Oct 29, 2018 · Synced Jul 21, 2026, 5:32 PM EDT
Completed Not applicable Interventional

Improving Safety of Diagnosis and Therapy in the Inpatient Setting

NCT04393909
View directory record Official record
Conditions
Delirium, Confusion, Mental Status Change, Back Pain, Hip Pain Chronic, Chest Pain, Asthma, COPD, Cellulitis, Soft Tissue Infections, Cough, Deep Vein Thrombosis, Pulmonary Embolism, Venous Thromboembolism, Dyspnea, Electrolyte Metabolism Abnormal, Fever, Failure to Thrive, Weakness, Protein-Calorie Malnutrition, Headache, Neck Pain, Hypoxia, Pneumonia, Sepsis, Syncope, Vomiting, Diarrhea, Leg Pain, Abdominal Pain
Interventions
Diagnostic Uncertainty Educational Curriculum, Diagnostic Timeout, Patient Diagnostic (Dx) Questionnaire, Enhancements to Epic-integrated Quality & Safety Dashboard
Behavioral
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
18 Years and older
Enrollment
700 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jul 25, 2022 · Synced Jul 21, 2026, 5:32 PM EDT
Completed Not applicable Interventional

Prevention of Hypergranulation Tissue After Gastrostomy Tube Placement

NCT01501539
View directory record Official record
Conditions
Soft Tissue Inflammation
Interventions
Standard Hydrocolloid Dressing, Silver Hydrocolloid Dressing
Procedure
Lead sponsor
Ann & Robert H Lurie Children's Hospital of Chicago
Other
Eligibility
1 Month to 17 Years
Enrollment
171 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2017
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Feb 7, 2018 · Synced Jul 21, 2026, 5:32 PM EDT
Recruiting Phase 1 Interventional

A Study of MQ710 With and Without Pembrolizumab in People With Solid Tumor Cancer

NCT05859074
View directory record Official record
Conditions
Cutaneous Squamous Cell Carcinoma, SCC - Squamous Cell Carcinoma, Basal Cell Carcinoma, BCC, BCC - Basal Cell Carcinoma, Melanoma, Merkel Cell Carcinoma, Sebaceous Carcinoma, Extramammary Paget Disease, Kaposi Sarcoma, Head and Neck Squamous Cell Carcinoma, HNSCC, Adnexal Carcinoma, Angiosarcoma, Cutaneous Neoplasm, Advanced Cancer, Metastatic Cancer, Refractory Cancer, Solid Tumor
Interventions
MQ719, Pembrolizumab
Biological · Drug
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older
Enrollment
56 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2028
U.S. locations
7
States / cities
Basking Ridge, New Jersey • Middletown, New Jersey • Montvale, New Jersey + 4 more
Source: ClinicalTrials.gov public record
Updated Dec 2, 2025 · Synced Jul 21, 2026, 5:32 PM EDT
Completed Phase 1 Interventional

Thalidomide and Docetaxel in Treating Patients With Advanced Cancer

NCT00049296
View directory record Official record
Conditions
Cancer
Interventions
docetaxel, thalidomide
Drug
Lead sponsor
Case Comprehensive Cancer Center
Other
Eligibility
18 Years and older
Enrollment
26 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2006
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Jun 10, 2010 · Synced Jul 21, 2026, 5:32 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Eligibility Screening for the NIH Intramural Research Program Clinical Protocols

NCT00026754
View directory record Official record
Conditions
Breast Cancer, Prostate Cancer, Lung Cancer, Sarcoma, Melanoma
Interventions
Not listed
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
1 Month and older
Enrollment
19,522 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2004 – 2024
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Apr 17, 2025 · Synced Jul 21, 2026, 5:32 PM EDT
Completed No phase listed Observational

The Registry of Oncology Outcomes Associated With Testing and Treatment

NCT04028479
View directory record Official record
Conditions
Adenocarcinoma, Adenocystic Carcinoma, Anal Cancer, Appendix Cancer, Brain Tumor, Glioblastoma, Astrocytoma, Bile Duct Cancer, Cholangiocarcinoma, Bladder Cancer, Bone Cancer, Synovial Sarcoma, Chondrosarcoma, Liposarcoma, Sarcoma, Kaposi, Sarcoma,Soft Tissue, Sarcoma, Osteosarcoma, CNS Cancer, Brain Stem Neoplasms, Breast Cancer, Cervical Cancer, Colorectal Cancer, Rectal Cancer, Colon Cancer, Esophageal Cancer, Esophagus Cancer, Cancer of Colon, Pancreatic Cancer, Cancer of Pancreas, Testis Cancer, Testicular Cancer, Ureter Cancer, Renal Cell Carcinoma, Kidney Cancer, Gestational Trophoblastic Tumor, Head and Neck Neoplasms, Parotid Tumor, Larynx Cancer, Tongue Cancer, Pharynx Cancer, Salivary Gland Cancer, Acute Myeloid Leukemia, Chronic Myeloid Leukemia, Acute Lymphoblastic Leukemia, Multiple Myeloma, Non Hodgkin Lymphoma, Carcinoid Tumor, Lung Cancer, Neuroendocrine Tumors, Mesothelioma, Thyroid Cancer, Parathyroid Neoplasms, Adrenal Cancer, Small Bowel Cancer, Stomach Cancer, Liver Cancer, Hepatic Cancer, Melanoma, Skin Cancer, Unknown Primary Tumors, Uterine Cancer, Fallopian Tube Cancer, Ovarian Cancer, Prostate Cancer, Vaginal Cancer, Penile Cancer, Vulvar Cancer, Waldenstrom Macroglobulinemia, Cancer, Advanced, Thymus Cancer, Nasopharyngeal Carcinoma, Multiple Endocrine Neoplasia, Pheochromocytoma, Small Cell Carcinoma, Pulmonary Carcinoma
Interventions
Biomarker Testing (L), Systemic Treatment (T), Patient Reported Outcomes (P)
Diagnostic Test · Drug · Other
Lead sponsor
Taproot Health
Industry
Eligibility
18 Years and older
Enrollment
167 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
2
States / cities
Idaho Falls, Idaho • Laredo, Texas
Source: ClinicalTrials.gov public record
Updated Dec 17, 2024 · Synced Jul 21, 2026, 5:32 PM EDT
Completed Not applicable Interventional Results available

Daptomycin for the Treatment of Severe Necrotizing Soft-Tissue Infections

NCT00261807
View directory record Official record
Conditions
Fasciitis, Necrotizing, Severe Necrotizing Skin and Soft Tissue Infections, Fournier's Gangrene
Interventions
Daptomycin 6mg/kg/day
Drug
Lead sponsor
University of Maryland, Baltimore
Other
Eligibility
18 Years and older
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2008
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Jan 26, 2022 · Synced Jul 21, 2026, 5:32 PM EDT
Completed Phase 1Phase 2 Interventional Results available

A Study of Tremelimumab and IV Durvalumab Plus Poly-ICLC in Subjects With Biopsy-accessible Cancers

NCT02643303
View directory record Official record
Conditions
Head and Neck Squamous Cell Carcinoma, Breast Cancer, Sarcoma, Merkel Cell Carcinoma, Cutaneous T-Cell Lymphoma, Melanoma, Renal Cancer, Bladder Cancer, Prostate Cancer, Testicular Cancer, Solid Tumor
Interventions
Durvalumab, Tremelimumab, Poly-ICLC
Drug
Lead sponsor
Ludwig Institute for Cancer Research
Other
Eligibility
18 Years and older
Enrollment
58 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2022
U.S. locations
7
States / cities
Atlanta, Georgia • Lebanon, New Hampshire • Buffalo, New York + 4 more
Source: ClinicalTrials.gov public record
Updated Dec 1, 2022 · Synced Jul 21, 2026, 5:32 PM EDT
Completed Phase 2 Interventional

Phase 2 Safety and Efficacy Study of Daptomycin in Complicated Skin and Skin Structure Infections

NCT00426933
View directory record Official record
Conditions
Soft Tissue Infections
Interventions
Daptomycin, Vancomycin
Drug
Lead sponsor
Cubist Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
Industry
Eligibility
18 Years to 85 Years
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007
U.S. locations
1
States / cities
Idaho Falls, Idaho
Source: ClinicalTrials.gov public record
Updated Sep 13, 2010 · Synced Jul 21, 2026, 5:32 PM EDT
Recruiting Phase 2 Interventional

Trial of Ixazomib for Kaposi Sarcoma

NCT04305691
View directory record Official record
Conditions
Kaposi Sarcoma, Skin
Interventions
Ixazomib Citrate, Quality-of-Life Assessment, Questionnaire Administration
Drug · Other
Lead sponsor
AIDS Malignancy Consortium
Network
Eligibility
18 Years and older
Enrollment
41 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2029
U.S. locations
10
States / cities
San Diego, California • San Francisco, California • Miami, Florida + 7 more
Source: ClinicalTrials.gov public record
Updated Feb 26, 2026 · Synced Jul 21, 2026, 5:32 PM EDT
Terminated Phase 1 Interventional

Photodynamic Therapy in Treating Patients With Skin Cancer or Solid Tumors Metastatic to the Skin

NCT00023790
View directory record Official record
Conditions
Breast Cancer, Head and Neck Cancer, Lymphoma, Metastatic Cancer, Non-melanomatous Skin Cancer, Sarcoma
Interventions
silicon phthalocyanine 4
Drug
Lead sponsor
Case Comprehensive Cancer Center
Other
Eligibility
18 Years and older
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2006
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Aug 23, 2011 · Synced Jul 21, 2026, 5:32 PM EDT
Completed Phase 2 Interventional

A Pilot, Open-Label, Phase II, Randomized Study to Determine the Effects of Viracept on the Outcome of Cutaneous and Mucosal KS in AIDS Patients With CD4 <= 500 Cells/mm3

NCT00002185
View directory record Official record
Conditions
Sarcoma, Kaposi, HIV Infections
Interventions
Nelfinavir mesylate
Drug
Lead sponsor
Agouron Pharmaceuticals
Industry
Eligibility
13 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
5
States / cities
Los Angeles, California • Orange, California • San Diego, California + 2 more
Source: ClinicalTrials.gov public record
Updated Jun 23, 2005 · Synced Jul 21, 2026, 5:32 PM EDT